Roblitinib

Roblitinib (FGF-401) is an orally active and highly selective FGFR4 inhibitor with an IC50 of 1.9 nM[1]. Roblitinib has antitumor activity[2].

Product Specifications

CAS Number

[1708971-55-4]

Product Name Alternative

FGF-401

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

FGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/FGF-401.html

Purity

99.67

Solubility

DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CN1CC(N(CC2=CC(CCCN3C(NC4=CC(NCCOC)=C(C#N)C=N4)=O)=C3N=C2C=O)CC1)=O

Molecular Formula

C25H30N8O4

Molecular Weight

506.56

Precautions

H302, H315, H319, H335

References & Citations

[1]Nicole Buschmann, et al. Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors. WO2015059668A1.|[2]Robin A Fairhurst, et al. Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. J Med Chem. 2020 Nov 12;63 (21) :12542-12573.